RBC Capital Calls XOMA's (XOMA) '358 'Sleeper Candidate'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
March 7, 2015 4:05 PM EST- Results show XOMA 358 reduces insulin receptor signaling and increased glucose production after exogenous insulin injection
- XOMA 358 shows potential for treatment of hyperinsulinemic hypoglycemia conditions
BERKELEY, Calif., March 7, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from XOMA 358, the lead antibody in the Company's XMet D program, today, at the Endocrine Society's Annual Meeting ENDO 2015. Paul Rubin, M.D., Senior Vice President, Research and Development, and Chief Medical Officer at XOMA, presented the Company's data, titled "XOMA 358, a Novel... More
